These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 21943517)

  • 1. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.
    Airavaara M; Harvey BK; Voutilainen MH; Shen H; Chou J; Lindholm P; Lindahl M; Tuominen RK; Saarma M; Hoffer B; Wang Y
    Cell Transplant; 2012; 21(6):1213-23. PubMed ID: 21943517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson's disease.
    Nam J; Richie CT; Harvey BK; Voutilainen MH
    Sci Rep; 2024 Jul; 14(1):16487. PubMed ID: 39019902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
    Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
    Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
    Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
    Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
    Lindholm P; Voutilainen MH; Laurén J; Peränen J; Leppänen VM; Andressoo JO; Lindahl M; Janhunen S; Kalkkinen N; Timmusk T; Tuominen RK; Saarma M
    Nature; 2007 Jul; 448(7149):73-7. PubMed ID: 17611540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
    Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
    eNeuro; 2017; 4(1):. PubMed ID: 28303260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
    Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
    Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
    Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
    Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
    Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
    FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
    Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
    Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
    Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
    J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by freshwater clam extract against the neurotoxin MPTP in C57BL/6 mice.
    Hsieh CC; Lin MS; Hua KF; Chen WJ; Lin CC
    Neurosci Lett; 2017 Mar; 642():51-58. PubMed ID: 28126590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.
    Tomac A; Lindqvist E; Lin LF; Ogren SO; Young D; Hoffer BJ; Olson L
    Nature; 1995 Jan; 373(6512):335-9. PubMed ID: 7830766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.